Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748696 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL31105723 | 1.00 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7747578 | 0.98 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL7747576 | 0.98 | MAPT (0.54) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Acetic Acid SCHEMBL21519428 | 0.91 | MAPT (0.55) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4698577 | 0.86 | MAPT (0.58) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4698447 | 0.86 | MAPT (0.58) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL17561003 | 0.84 | MAPT (0.56) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL21538104 | 0.83 | KMT2A (0.64) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL28884203 | 0.83 | GAA (0.68) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001025192-A1 | GUANIDINE DERIVATIVES AND THEIR USE IN THE PRODUCTION OF A MEDICAMENT FOR BLOCKING XANTHINE OXIDASE/DEHYDROGENASE | MELACURE THERAPEUTICS AB (SE) | 2001-04-12 | — | — | WO | claimed |
| US-10954198-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20200289436-A1 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES | INFLECTIS BIOSCIENCE (FR) | 2020-09-17 | — | — | US | disclosed |
| US-10709677-B2 | Therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | INFLECTIS BIOSCIENCE (FR) | 2020-07-14 | — | — | US | disclosed |
| US-20200095210-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | INFLECTIS BIOSCIENCE (FR) | 2020-03-26 | — | — | US | disclosed |
| US-20180354914-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | MEDICAL RESEARCH COUNCIL (GB) | 2018-12-13 | — | — | US | disclosed |
| US-10100020-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2018-10-16 | — | — | US | disclosed |
| US-20170247344-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9682943-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | MEDICAL RESEARCH COUNCIL (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170151196-A1 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES | INFLECTIS BIOSCIENCE (FR) | 2017-06-01 | — | — | US | disclosed |
| EP-3115357-A1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | Medical Research Council (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2943467-B1 | BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES | MEDICAL RES COUNCIL (GB) | 2016-07-13 | — | — | EP | disclosed |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095210-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | MAPT 241/4885SMN1; SMN2 178/4885NPC1 2664/4885 |
| US-20170247344-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | MAPT 241/4885SMN1; SMN2 178/4885NPC1 2664/4885 |
| US-10709677-B2 | Therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies | PPP1R15A, PPP1R15B, PPP3R1 | MAPT 67/4885SMN1; SMN2 180/4885NPC1 2006/4885 |
| US-10100020-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | ATXN2L, BCL9L, ATXN10 | MAPT 241/4885SMN1; SMN2 178/4885NPC1 2664/4885 |
| US-20180354914-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | RTN3, ATXN2L, PARK7 | MAPT 330/4885SMN1; SMN2 253/4885NPC1 3048/4885 |
| US-20170151196-A1 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES | PPP1R15A, PPP1R15B, PSMG3 | MAPT 79/4885SMN1; SMN2 190/4885NPC1 2187/4885 |
| US-20160046589-A1 | Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases | ATXN2L, BCL9L, ATXN10 | MAPT 241/4885SMN1; SMN2 178/4885NPC1 2664/4885 |
| US-10954198-B2 | Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases | ATXN2L, BCL9L, ATXN10 | MAPT 241/4885SMN1; SMN2 178/4885NPC1 2664/4885 |
| US-20200289436-A1 | NOVEL THERAPEUTIC USES OF BENZYLIDENEGUANIDINE DERIVATIVES FOR THE TREATMENT OF PROTEOPATHIES | PPP1R15A, PPP1R15B, PSMG3 | MAPT 76/4885SMN1; SMN2 161/4885NPC1 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.